ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 117 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q3 2019. The put-call ratio across all filers is 0.95 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $320 | +19.0% | 58,720 | +46.6% | 0.00% | +100.0% |
Q2 2023 | $269 | -60.4% | 40,062 | -47.9% | 0.00% | -75.0% |
Q1 2023 | $679 | +207.2% | 76,854 | +165.4% | 0.01% | +166.7% |
Q4 2022 | $221 | -99.9% | 28,962 | +22.6% | 0.00% | +50.0% |
Q3 2022 | $168,000 | -59.0% | 23,623 | -53.4% | 0.00% | -50.0% |
Q2 2022 | $410,000 | +17.1% | 50,678 | +100.8% | 0.00% | +33.3% |
Q1 2022 | $350,000 | -47.8% | 25,239 | +5.7% | 0.00% | -25.0% |
Q4 2021 | $670,000 | +85.6% | 23,876 | +124.9% | 0.00% | +100.0% |
Q3 2021 | $361,000 | +15.7% | 10,614 | +38.8% | 0.00% | +100.0% |
Q2 2021 | $312,000 | -70.5% | 7,645 | -70.9% | 0.00% | -83.3% |
Q1 2021 | $1,059,000 | +789.9% | 26,301 | +1203.3% | 0.01% | +500.0% |
Q4 2020 | $119,000 | -77.7% | 2,018 | -81.6% | 0.00% | -66.7% |
Q3 2020 | $534,000 | +173.8% | 10,982 | +68.4% | 0.00% | +50.0% |
Q4 2019 | $195,000 | -73.1% | 6,520 | -56.5% | 0.00% | -60.0% |
Q2 2019 | $724,000 | – | 15,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 3,030,434 | $23,152,516 | 15.55% |
BERYLSON CAPITAL PARTNERS, LLC | 289,726 | $2,213,507 | 6.45% |
Matrix Capital Management Company, LP | 11,572,590 | $88,414,588 | 1.69% |
Pier Capital, LLC | 1,012,401 | $7,734,744 | 1.27% |
VIKING GLOBAL INVESTORS LP | 29,993,708 | $229,151,929 | 1.15% |
Eagle Health Investments LP | 607,860 | $4,644,050 | 1.07% |
Triatomic Management LP | 130,805 | $999,350 | 0.84% |
Aristotle Atlantic Partners, LLC | 1,880,567 | $14,367,532 | 0.80% |
Senator Investment Group LP | 1,000,000 | $7,640,000 | 0.69% |
ARK Investment Management | 9,201,245 | $70,297,512 | 0.61% |